Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination
Measurement of quantitative antibody responses are increasingly important in evaluating the immune response to infection and vaccination. In this study we describe the validation of a quantitative, multiplex serologic assay utilising an electrochemiluminescence platform, which measures IgG against the receptor binding domain (RBD), spike S1 and S2 subunits and nucleocapsid antigens of SARS-CoV-2. The assay displayed a sensitivity ranging from 73 to 91% and specificity from 90 to 96% in detecting previous infection with SARS-CoV-2 depending on antigenic target and time since infection, and this assay highly correlated with commercially available assays. The within-plate coefficient of variation ranged from 3.8-3.9% and the inter-plate coefficient of variation from 11 to 13% for each antigen.
Science Foundation Ireland (grant numbers 20/COV/0305 and 20/COV/8549)
VACCELERATE the European Corona Vaccine Trial Accelerator Platform
United States Embassy in Ireland
CommentsThe original article is available at https://www.sciencedirect.com/
Published CitationKenny G, et al. Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination. J Immunol Methods. 2022;510:113345.
Publication Date30 August 2022
- Beaumont Hospital
- International Health and Tropical Medicine
- Published Version (Version of Record)